Bio Sig Technologies, Inc. BSGM
We take great care to ensure that the data presented and summarized in this overview for BioSig Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BSGM
View allLatest Institutional Activity in BSGM
Top Purchases
Top Sells
About BSGM
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Insider Transactions at BSGM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2024
|
Anthony N. Amato Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,550,000
+31.25%
|
-
|
|
Jul 26
2024
|
Christopher Allen Baer Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jul 26
2024
|
Steven Eric Abelman Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jul 26
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+4.84%
|
-
|
|
Jul 26
2024
|
Donald Browne Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+27.27%
|
-
|
|
Jun 07
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+8.2%
|
-
|
|
Mar 01
2024
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+49.53%
|
-
|
|
Nov 30
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
219,700
+7.46%
|
-
|
|
Aug 15
2023
|
Frederick Hrkac Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+14.41%
|
-
|
|
Aug 15
2023
|
James L Klein Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+5.08%
|
-
|
|
Aug 15
2023
|
Iv David Weild Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+12.21%
|
-
|
|
Aug 15
2023
|
Patrick Joseph Gallagher Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+8.23%
|
-
|
|
Aug 15
2023
|
James J Barry Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+14.41%
|
-
|
|
Aug 15
2023
|
Donald E Foley Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+6.72%
|
-
|
|
Jun 13
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,600
+0.16%
|
$15,600
$1.24 P/Share
|
|
Jun 12
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.08%
|
$6,000
$1.17 P/Share
|
|
Jun 02
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,600
+0.05%
|
$4,600
$1.39 P/Share
|
|
May 31
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,000
+0.05%
|
$8,000
$1.57 P/Share
|
|
May 05
2023
|
Gray Fleming Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,620
+47.13%
|
-
|
|
May 05
2023
|
Kenneth L Londoner Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
576,000
+18.89%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.44M shares |
|---|